It has been shown that inhibition of LAPTM5 blocks bladder cancer cell proliferation and cell cycle via deactivation of ERK1/2 and p38 [121] and that silencing of STK32C inhibited tumor cell proliferation, migration, and invasion in human bladder cancer cells [99]. Here, LAPTM5 is linked to urinary bladder carcinoma.